📊 CPMV Key Takeaways
Investment Thesis
Mosaic ImmunoEngineering exhibits severe financial distress with negative stockholders' equity of -$7.3M, liabilities exceeding assets by a substantial margin, and minimal operating capacity. The company is burning cash with negative operating cash flow of -$83.3K, deteriorating liquidity ratios (0.01x current ratio), and lacks meaningful revenue generation, making continued operations unsustainable without significant capital infusion or restructuring.
CPMV Strengths
- Minimal capital expenditure requirements suggest low ongoing operational needs
- Small absolute scale of cash burn provides limited time before complete depletion
- Historical data suggests some previous gross profit generation capability
CPMV Risks
- Negative stockholders' equity indicating technical insolvency and potential equity wipeout
- Critical liquidity crisis with current ratio of 0.01x and only $31.8K cash against $7.4M liabilities
- Negative operating cash flow combined with revenue N/A indicates non-viable business model
- Net losses continuing to accumulate with persistent operating deficits
- Zero insider activity in last 90 days suggests management disengagement
- Extremely poor asset efficiency with -938% ROA
Key Metrics to Watch
- Stockholders equity trajectory toward reorganization or dissolution
- Cash burn rate and months of cash runway remaining
- Revenue generation attempts and gross margin sustainability
CPMV Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
CPMV Profitability Ratios
CPMV vs Healthcare Sector
How Mosaic ImmunoEngineering Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CPMV Balance Sheet & Liquidity
CPMV 5-Year Financial Trend
5-Year Trend Summary: Mosaic ImmunoEngineering Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.14 indicates the company is currently unprofitable.
CPMV Growth Metrics (YoY)
CPMV Capital Allocation
CPMV SEC Filings
Access official SEC EDGAR filings for Mosaic ImmunoEngineering Inc. (CIK: 0000836564)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CPMV
What is the AI rating for CPMV?
Mosaic ImmunoEngineering Inc. (CPMV) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CPMV's key strengths?
Minimal capital expenditure requirements suggest low ongoing operational needs. Small absolute scale of cash burn provides limited time before complete depletion.
What are the risks of investing in CPMV?
Negative stockholders' equity indicating technical insolvency and potential equity wipeout. Critical liquidity crisis with current ratio of 0.01x and only $31.8K cash against $7.4M liabilities.
What is CPMV's revenue and growth?
Mosaic ImmunoEngineering Inc. reported revenue of N/A.
Does CPMV pay dividends?
Mosaic ImmunoEngineering Inc. does not currently pay dividends.
Where can I find CPMV SEC filings?
Official SEC filings for Mosaic ImmunoEngineering Inc. (CIK: 0000836564) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CPMV's EPS?
Mosaic ImmunoEngineering Inc. has a diluted EPS of $-0.07.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.